The Food and Drug Administration Safety and Innovation Act, signed into law in 2012, requires the FDA, in consultation with the Federal Communications Commission and the ONC, to develop a strategy and recommendations for a framework to promote innovation and protect patient safety. A workgroup was formed in early 2013 to formulate guidance on the issue.
At HIMSS 14, the director of the FDA’s Center for Devices and Radiological Health announced next month’s internal deadline, while stressing the draft guidance’s role not as a definitive rule, but as the start of a conversation.
The scope of FDA regulation for health IT products has been discussed recently in Congress. The Preventing Regulatory Overreach To Enhance Care Technology Act of 2014, introduced this month in the Senate, would remove FDA oversight from health IT products not used for diagnostic purposes, including EHRs and many medical devices and mobile apps. This bill mirrors the SOFTWARE Act, introduced in the House last October.
More Articles on FDA Regulation:
FDA Bans Ranbaxy Laboratories From Manufacturing, Importing Drugs
FDA Issues Draft Guidance on Custom Device Exemption Implementation
U.S. Biomedical Research is Slipping — What it Means for U.S. Innovation
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
